Friday, June 24, 2022

Innovus Pharmaceuticals, Inc. (OTMKTS:INNV) Sees Dip but Builds Distribution Reach

Innovus Pharmaceuticals, Inc. (OTMKTS:INNV) has seen a dip in price today, even as the company released some good news. INNV  announced today that its distribution partner, Densmore Pharmaceutical International, a company based in Monaco, recently launched the Company’s Zestra product in France, Belgium and Monaco. The product, which I detail below, is a commercial pharmaceutical option that acts as an arousal stimulant for women.
“We are pleased to announce the launch of Zestra® in three additional European countries by our distribution partner, Densmore,” said Innovus Pharma CEO, Dr. Bassam Damaj. “We believe that Europe will become a major market for Zestra® and that our European and international distribution partners will continue to grow our ex-US sales of this and other of our products in this third quarter 2017 and beyond,” continued Dr. Damaj.
Innovus Pharmaceuticals, Inc. (OTCMKTS: INNV), a pharmaceutical company, engages in the commercialization, licensing, and development of non-prescription medicine and consumer care products in the United States.
The company’s products include Zestra, a non-medicated patented consumer care product to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph-compliant benzocaine-based topical gel for treating premature ejaculation; Sensum+, a non-medicated consumer care cream that enhances penile sensitivity; Zestra Glide, a high viscosity and low osmolality water-based lubricant; Vesele, a proprietary oral dietary supplement to enhance nitric oxide beneficial clinical effects on sexual functions and brain health; and Androferti to support overall male reproductive health and sperm quality.
INNV also has a number of product lines gestating in the pipeline, including FlutiCare, an over the counter drug for Rhinitis; Urocis for urinary tract infection; and AndroVit, a proprietary supplement to support overall prostate and male sexual health.
In response to the company’s recent surge in topline growth, INNV investors have been rewarded by upgrades to future outlooks by both SeeThruEquity and Zack’s research. Price targets now reach as high as $1/share and above.
Find out when INNV stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.


“We are excited to launch such a unique and patented product as Zestra® with strong clinical trials in Female Sexual Dysfunction, a large and unmet medical need dysfunction with no efficacious treatments available to patients,” said Dr. Philippe Caron, President & CEO of Densmore Labs.
INNV is a stock who’s past is littered with sudden rips, and this should effectively constitute the idea of bad news now being out of the way, so it may pay to keep an eye on this stock.
Innovus Pharmaceuticals, Inc. (OTMKTS:INNV) is truly a roller-coaster stock. The volatility is just omnipresent here. A true biotech. INNV has a $14.93M market cap with 151.30M in outstanding shares and needs to be watched, as always. This stock has some legitimate products, so investors need to be paying attention. Sign-up for continuing coverage on shares of $INNV stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: We hold no position in $INNV, either long or short, and we have not been compensated for this article.

Related Articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Stay Connected

0FansLike
3,360FollowersFollow
19,700SubscribersSubscribe

Latest Articles